Redeye is encouraged by the preliminary Q4 (Oct-Nov) sales, and we positively review the sales estimates for Catalyst for 2023e-2025e. While a good sign on the roll-out of Catalyst (further increasing our confidence in our take on the case), we reiterate our fair value range. We highlight the significant discount OssDsign is trading at compared to its peers, further cementing our thesis of a strong share price development into next year.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

OssDsign - Higher-than-expected Q4 preliminary sales

© Modular Finance, source Nordic Press Releases